An Open-Label Pharmacokinetics and Safety Study of Talazoparib

Pfizer34 enrolled

Overview

This trial will investigate the pharmacokinetics (PK) and safety of talazoparib in patients with advanced solid tumors and impaired renal function.

At the End of the Study, patients with no clinically significant toxicities, no contraindications to continue treatment with talazoparib, and no disease progression (underlying cancer progression) may be eligible to continue talazoparib treatment in a separate open-label extension study after discussion with the Principal Investigator and obtaining Sponsor permission. Sponsor decision to allow the patient to continue dosing with talazoparib in an open-label extension study will be based on potential overall benefit-risk, patient acceptance and other relevant criteria.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Advanced Solid Tumors

Interventions

TalazoparibDRUG

Daily oral doses of talazoparib 0.5 mg

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Signed and dated informed consent form (by the patient or a legally acceptable representative as per the local regulations) obtained prior to initiation of any study-specific procedure and treatment. 2. Female or male of at least 18 years of age. 3. Histologically or cytologically confirmed advanced solid tumor with no available standard approved treatment options in the opinion of the Investigator 4. Eastern Cooperative Oncology Group (ECOG) Performance status (PS) ≤ 2. 5. Expected life expectancy of ≥ 3 months. 6. Able to swallow the study drug (no contra indication to oral agents). 7. Renal function at screening and enrollment as defined by the Modification of Diet in Renal Disease (MDRD) equation. 8. Patient has had no clinically significant change in renal status within 3 months prior to screening, according to Investigator's review of clinical patient records. 9. Patient is not currently on hemodialysis and/or peritoneal dialysis for management of chronic kidney disease or acute failure/conditions. 10. Patient has no unstable renal function, defined as a change in estimated glomerular filtration rate (eGFR) (calculated with the MDRD equation) of \> 25% for patients with mild and moderate renal impaired or as a change in eGFR \> 30% for patients with severe renal impaired, from screening to enrollment. 11. Adequate other organ function at screening and enrollment. 12. Female patients of childbearing potential must have a negative serum pregnancy test at screening, and must agree to use a highly effective birth control method from the time of the first dose of study drug through 45 days after the last dose of study drug. 13. Male patients must agree to use a condom when having sex with a pregnant woman or with a non-pregnant female partner of childbearing potential, from 21 days before the first dose of study drug through 105 days after last dose of study drug. 14. Female patients must not be breastfeeding at screening nor during the study participation until 45 days after the last dose of study drug. 15. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures. Exclusion Criteria: 1. Treatment within 14 days or five half lives prior to enrollment with any type of systemic anticancer-therapy or any investigational drug, whichever is longer. 2. Have not recovered (recovery is defined as CTCAE grade ≤ 1) from the acute toxicities of previous anticancer standard or investigational therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements. 3. Major surgery within 28 days prior to enrollment. 4. Serious accompanying cardiac disorder. 5. Active known or suspected brain metastasis or active leptomeningeal disease undergoing or requiring treatment. 6. Symptomatic or impending spinal cord compression or cauda equina syndrome. 7. Has undergone a liver transplant, kidney transplant or nephrectomy. 8. Prior allergic reaction or severe intolerance (meeting the criteria for a serious adverse event, a grade 3 or 4 AE, or permanent treatment discontinuation) to a poly ADP ribose polymerase (PARP) inhibitor. 9. Known myelodysplastic syndrome. 10. Seropositive for human immunodeficiency virus (HIV). 11. Any serious or unstable medical condition that interferes with ability to tolerate treatment or assessments associated with the protocol. 12. Gastrointestinal disorder affecting absorption. 13. Known or suspected hypersensitivity to any of the talazoparib capsule components. 14. Any condition or reason that interferes with ability to participate in the study, tolerate treatment or assessments associated with the protocol, causes undue risk, or complicates the interpretation of safety data, in the opinion of the Investigator or Medical Monitor.

Locations (10)

Fort Wayne Medical Oncology and Hematology, Inc.

Fort Wayne, Indiana, United States

Fort Wayne Medical Oncology and Hematology, Inc.

Fort Wayne, Indiana, United States

Karmanos Cancer Institute

Detroit, Michigan, United States

Outcomes

Primary Outcomes

Multiple Dose: Area Under the Concentration Time Curve From 0 to 24 Hours (AUC0-24) of Talazoparib

AUC0-24 of talazoparib was defined as the area under the concentration time curve from time 0 to 24 hours post-dose.

Time frame: Predose, 0.5, 1, 2, 4, 6, 8 to 12, and 24 hours post-dose on Day 22

Multiple Dose: Maximum Observed Plasma Concentration (Cmax) of Talazoparib

Cmax was defined as the maximum observed plasma concentration of talazoparib.

Time frame: Predose, 0.5, 1, 2, 4, 6, 8 to 12, and 24 hours post-dose on Day 22

Multiple Dose: Area Under the Curve From Time 0 to 24 Hours for Unbound (AUC0-24u) Talazoparib

AUC0-24u for unbound talazoparib was defined as the area under the concentration time curve from time 0 to 24 hours post-dose.

Time frame: Predose, 0.5, 1, 2, 4, 6, 8 to 12, and 24 hours post-dose on Day 22

Multiple Dose: Maximum Observed Plasma Concentration for Unbound (Cmaxu) Talazoparib

Cmaxu was defined as the maximum observed plasma concentration for unbound talazoparib.

Time frame: Predose, 0.5, 1, 2, 4, 6, 8 to 12, and 24 hours post-dose on Day 22

Secondary Outcomes

Single Dose: Area Under the Concentration Time Curve From 0 to 24 Hours (AUC0-24) of Talazoparib

AUC0-24 of talazoparib was defined as the area under the concentration time curve from time 0 to 24 hours post-dose.

Time frame: Predose, 0.5, 1, 2, 4, 6, 8 to 12, and 24 hours post-dose on Day 1

Single Dose: Maximum Observed Plasma Concentration (Cmax) of Talazoparib

Cmax was defined as the maximum observed plasma concentration of talazoparib.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Karmanos Cancer Institute Weisberg Cancer Treatment Center

Farmington Hills, Michigan, United States

Robert Wood Johnson University Hospital

New Brunswick, New Jersey, United States

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Cross Cancer Institute

Edmonton, Alberta, Canada

Juravinski Cancer Centre

Hamilton, Ontario, Canada

Jewish General Hospital

Montreal, Quebec, Canada

Time frame: Predose, 0.5, 1, 2, 4, 6, 8 to 12, and 24 hours post-dose on Day 1

Single Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Talazoparib

Tmax was defined as the time to reach maximum observed plasma concentration of talazoparib.

Time frame: Predose, 0.5, 1, 2, 4, 6, 8 to 12, and 24 hours post-dose on Day 1

Single Dose: Fraction of Unbound Drug (Fu) in Plasma in Talazoparib

Fraction of unbound drug (fu) was defined as the ratio of unbound drug concentration to the total drug concentration.

Time frame: Predose, 0.5, 1, 2, 4, 6, 8 to 12, and 24 hours post-dose on Day 1

Single Dose: Area Under the Curve From Time 0 to 24 Hour for Unbound (AUC0-24u) Talazoparib

AUC0-24u for unbound talazoparib was defined as the area under the concentration time curve from time 0 to 24 hours for unbound talazoparib.

Time frame: Predose, 0.5, 1, 2, 4, 6, 8 to 12, and 24 hours post-dose on Day 1

Single Dose: Maximum Observed Plasma Concentration for Unbound (Cmaxu) Talazoparib

Cmaxu was defined as the maximum observed plasma concentration for unbound talazoparib.

Time frame: Predose, 0.5, 1, 2, 4, 6, 8 to 12, and 24 hours post-dose on Day 1

Multiple Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Talazoparib

Tmax was defined as the time to reach maximum observed plasma concentration of talazoparib.

Time frame: Predose, 0.5, 1, 2, 4, 6, 8 to 12, and 24 hours post-dose on Day 22

Multiple Dose: Plasma Trough Concentration (Ctrough) of Talazoparib

Ctrough was defined as plasma trough (predose) concentration of talazoparib.

Time frame: Predose on Day 22

Multiple Dose: Apparent Oral Clearance (CL/F) of Talazoparib

Drug clearance is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

Time frame: Predose, 0.5, 1, 2, 4, 6, 8 to 12, and 24 hours post-dose on Day 22

Multiple Dose: Accumulation Ratio (Rac) of AUC (0-24)

Accumulation ratio for AUC0-24 was calculated as area under the curve from time zero to 24 hours on Day 22 divided by area under the curve from time zero to 24 hours on Day 1.

Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8 to 12, and 24 hours post-dose on Day 1 and Day 22

Multiple Dose: Fraction of Unbound Drug (Fu) in Plasma in Talazoparib

Fraction of unbound drug (fu) was defined as the ratio of unbound drug concentration to the total drug concentration.

Time frame: Predose, 0.5, 1, 2, 4, 6, 8-12, and 24 hours post-dose on Day 22

Multiple Dose: Unbound Apparent Oral Clearance (CLu/F) of Talazoparib

Clearance of unbound drug is a measure of the rate at which unbound drug is metabolized or eliminated by normal biological processes.

Time frame: Predose, 0.5, 1, 2, 4, 6, 8-12, and 24 hours post-dose on Day 22

Single Dose: Amount of Talazoparib Excreted Unchanged in Urine From Time 0 to 24 Hours (Ae 0-24)

Ae 0-24 is the amount of drug excreted unchanged in urine from time 0 to 24 hours postdose.

Time frame: 0 to 24 hours on Day 1

Single Dose: Percentage of Dose of Talazoparib Excreted in Urine From Time 0 to 24 Hours (Ae 0-24%) at Day 1

Ae0-24% was defined as the amount of drug excreted in urine from time 0 to 24 hours expressed as percentage of administered dose.

Time frame: 0 to 24 hours on Day 1

Multiple Dose: Amount of Talazoparib Excreted in Urine From Time 0 to 24 Hours (Ae 0-24%)

Ae 0-24 is the amount of drug excreted unchanged in urine from time 0 to 24 hours postdose.

Time frame: 0 to 24 hours on Day 22

Multiple Dose: Percentage of Talazoparib Excreted in Urine From Time 0 to 24 Hours (Ae 0-24 %) of Talazoparib at Day 22

Ae 0-24% was defined as the amount of drug excreted in urine from time 0 to 24 hours, expressed as percentage of administered dose.

Time frame: 0 to 24 hours on Day 22

Multiple Dose: Renal Clearance (CLr) of Talazoparib at Day 22

Renal clearance was calculated as cumulative amount of drug excreted in urine during the 24 hours dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to 24 hours postdose.

Time frame: 0 to 24 hours on Day 22

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent were events between first dose of investigational product and up to 30 days after the last dose of investigational product (up to 52 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.

Time frame: Baseline up to 30 days after last dose of study drug (up to 52 days)

Number of Participants With Abnormalities in Physical Examination

Physical examination included examination of the general appearance, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. Findings were considered to be abnormal based on investigator's decision.

Time frame: Baseline up to 30 days after last dose of study drug (up to 52 days)

Change From Baseline in Systolic Blood Pressure (SBP) of Participants

Time frame: Baseline, Day 8, Day 15, Day 22, Safety follow up (Day 52)

Change From Baseline in Diastolic Blood Pressure (DBP) of Participants

Time frame: Baseline, Day 8, Day 15, Day 22, Safety follow up (Day 52)

Change From Baseline in Heart Rate of Participants

Heart rate was measured in terms of beats per minute.

Time frame: Baseline, Day 8, Day 15, Day 22, Safety follow up (Day 52)

Change From Baseline in Respiratory Rate of Participants

Respiratory rate was measured in terms of breaths per minute.

Time frame: Baseline, Day 8, Day 15, Day 22, Safety follow up (Day 52)

Change From Baseline in Body Weight of Participants

Time frame: Baseline, Day 8, Day 15, Day 22, Safety follow up (Day 52)

Number of Participants With Electrocardiogram (ECG) Abnormalities

ECG parameters included pulse rate (PR) interval, QRS duration, QT interval and corrected QT interval using Fridericia's formula (QTcF). Abnormality criteria: 1) PR interval: greater than equal to (\>=) 25 percent (%) increase when baseline \>= 300 msec; 2) QRS duration: \>=50% increase when baseline \>=140 msec; 3) QT interval: \>= 500 msec: 4) QTCF interval: QTc interval using Fridericia's formula (QTcF interval) \>= 500 msec when baseline \>= 60. IFB stands for increase from baseline.

Time frame: Baseline up to 30 days after last dose of study drug (up to 52 days)

Number of Participants With Laboratory Abnormalities

Laboratory parameters: erythrocytes, hematocrit, hemoglobin, white blood cells, absolute neutrophil count, lymphocytes, platelets ; albumin, alkaline phosphatase, alanine aminotransferase, aspartate transaminase , bilirubin, bicarbonate, blood urea nitrogen , calcium, chloride, creatinine, gamma -glutamyl transferase, glucose, lactate dehydrogenase, sodium, phosphate, potassium, total protein, uric acid, follicle-stimulating hormone; international normalized ratio / prothrombin time \[activated\] partial thromboplastin time; Urinalysis (pH, specific gravity, protein, glucose, ketones, bilirubin, blood, leukocyte esterase); Serum pregnancy test; Serology for Human Immunodeficiency Virus (HIV). Number of participants with laboratory test abnormalities as per National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) version 4.03 were reported: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.

Time frame: Baseline up to 30 days after last dose of study drug (up to 52 days)

Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status

As per ECOG, participant's performance status was measured on 5 point scale: 0=fully active/able to carry on all pre-disease activities without restriction; 1= restricted in physically strenuous activity but ambulatory and able to carry out work of a light and sedentary nature, e.g., light housework, office work. 2= ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours; 3=capable of only limited self-care, confined to bed/chair \>50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed/chair: 5: dead.

Time frame: Baseline, Safety follow up (Day 52)